Literature DB >> 32399924

Evasion of Host Immunity During Fasciola hepatica Infection.

Robin J Flynn1, Mayowa Musah-Eroje2.   

Abstract

Fasciola hepatica, the common liver fluke, causes infection of livestock throughout temperate regions of the globe. This helminth parasite has an indirect lifecycle, relying on the presence of the mud snail to complete its transition from egg to definitive host (Beesley et al., Transbound Emerg Dis 65:199-216, 2017). Within the definitive host, the parasite excysts in the intestine forming a newly excysted juvenile (NEJ) and migrates via the peritoneal cavity to the liver. Disease resulting from infection can be acute or chronic depending on the host and the number of parasites present. Sheep may succumb to a fatal acute infection if the challenge of metacercariae is great enough. However, in cattle chronic disease is the most likely outcome with parasites surviving for long periods of time. Annual losses are estimated to be in the region of US$ 2000 million to the agricultural industry (Beesley et al., Transbound Emerg Dis 65:199-216, 2017). Management of the disease depends heavily on chemotherapy with triclabendazole being the drug of choice, consistent use for over 20 years has resulted in drug-resistant strains emerging worldwide (Beesley et al., Int J Parasitol 47:11-20, 2017). A more sustainable approach to control would be through vaccination and indeed a lead candidate has been identified, cathepsin L1. Despite these promising results the parasite continues to confound our own and host efforts to generate long-lasting and effective immunity. In this brief review we focus our attention on those mechanisms that the parasite utilises to circumvent the innate based defense mechanisms within the host.

Entities:  

Keywords:  Cathepsin; Fasciola hepatica; Helminth; Immune evasion; Immunomodulatory; Innate immunity

Mesh:

Year:  2020        PMID: 32399924     DOI: 10.1007/978-1-0716-0475-5_8

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  46 in total

1.  Responses of Fasciola hepatica infected sheep to various infection levels.

Authors:  A Chauvin; E Moreau; C Boulard
Journal:  Vet Res       Date:  2001 Jan-Feb       Impact factor: 3.683

2.  Cell-mediated immune response in calves to single-dose, trickle, and challenge infections with Fasciola hepatica.

Authors:  K Bossaert; E Jacquinet; J Saunders; F Farnir; B Losson
Journal:  Vet Parasitol       Date:  2000-02-29       Impact factor: 2.738

Review 3.  Coordinating innate and adaptive immunity in Fasciola hepatica infection: implications for control.

Authors:  Robin J Flynn; Grace Mulcahy; Hany M Elsheikha
Journal:  Vet Parasitol       Date:  2010-02-18       Impact factor: 2.738

4.  Schistosoma mansoni infection in eosinophil lineage-ablated mice.

Authors:  Jonathan M Swartz; Kimberly D Dyer; Allen W Cheever; Thirumalai Ramalingam; Lesley Pesnicak; Joseph B Domachowske; James J Lee; Nancy A Lee; Paul S Foster; Thomas A Wynn; Helene F Rosenberg
Journal:  Blood       Date:  2006-06-13       Impact factor: 22.113

5.  Fasciola hepatica and Fasciola gigantica: comparison of cellular response to experimental infection in sheep.

Authors:  W Y Zhang; E Moreau; J C Hope; C J Howard; W Y Huang; A Chauvin
Journal:  Exp Parasitol       Date:  2005-08-26       Impact factor: 2.011

6.  The roles of IL-10 and TGF-beta in controlling IL-4 and IFN-gamma production during experimental Fasciola hepatica infection.

Authors:  Robin J Flynn; Grace Mulcahy
Journal:  Int J Parasitol       Date:  2008-06-18       Impact factor: 3.981

7.  Resistance of the rat to reinfection with Fasciola hepatica and the possible involvement of intestinal eosinophil leucocytes.

Authors:  T G Doy; D L Hughes; E Harness
Journal:  Res Vet Sci       Date:  1978-07       Impact factor: 2.534

8.  The Chronic Stages of Bovine Fasciola hepatica Are Dominated by CD4 T-Cell Exhaustion.

Authors:  Divya Sachdev; Kevin C Gough; Robin J Flynn
Journal:  Front Immunol       Date:  2017-08-21       Impact factor: 7.561

9.  Fasciola hepatica demonstrates high levels of genetic diversity, a lack of population structure and high gene flow: possible implications for drug resistance.

Authors:  Nicola J Beesley; Diana J L Williams; Steve Paterson; Jane Hodgkinson
Journal:  Int J Parasitol       Date:  2016-12-07       Impact factor: 3.981

Review 10.  Fasciola and fasciolosis in ruminants in Europe: Identifying research needs.

Authors:  N J Beesley; C Caminade; J Charlier; R J Flynn; J E Hodgkinson; A Martinez-Moreno; M Martinez-Valladares; J Perez; L Rinaldi; D J L Williams
Journal:  Transbound Emerg Dis       Date:  2017-10-06       Impact factor: 5.005

View more
  1 in total

1.  Recombinant Fasciola hepatica Fatty Acid Binding Protein as a Novel Anti-Inflammatory Biotherapeutic Drug in an Acute Gram-Negative Nonhuman Primate Sepsis Model.

Authors:  Jose J Rosado-Franco; Albersy Armina-Rodriguez; Nicole Marzan-Rivera; Armando G Burgos; Natalie Spiliopoulos; Stephanie M Dorta-Estremera; Loyda B Mendez; A M Espino
Journal:  Microbiol Spectr       Date:  2021-12-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.